Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of Kaempferoside in the Preparation of Anti-non-small Cell Lung Cancer Drugs

A technology for non-small cell lung cancer and kaempferol, which is used in antitumor drugs, drug combinations, pharmaceutical formulations, etc.

Active Publication Date: 2022-04-08
朱峰
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

People's functional research on Aurora is still largely limited to the study of mitosis, and the limitations of its functional understanding are also reflected in the research on its inhibitors: there is still no Aurora kinase inhibitor that has passed Phase III clinical trials [14]

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of Kaempferoside in the Preparation of Anti-non-small Cell Lung Cancer Drugs
  • Use of Kaempferoside in the Preparation of Anti-non-small Cell Lung Cancer Drugs
  • Use of Kaempferoside in the Preparation of Anti-non-small Cell Lung Cancer Drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] Example 1 Determined that AurkC is highly expressed in NSCLC drug-resistant cell lines by Western Blot experiment

[0057] experiment method:

[0058] HCC827 and HCC827GR cells in the logarithmic growth phase were digested with 0.25% trypsin to form a cell suspension, counted, and seeded 3×10 in a 10 cm culture dish. 6 cells, 37°C, 5% CO 2 Cultivate in the incubator for 24h. When the cell density reaches 80%, discard the clean medium, add 300μL RIPA to lyse the cells, collect the lysed cells into a 1.5mL EP tube, sonicate three times, 15 seconds each time, centrifuge at 12000rpm for 10 minutes, transfer the supernatant to a new tube In EP tube. Western Blot detection of related molecules.

[0059] results and analysis:

[0060] Depend on figure 1 It can be seen that MET, Aurk and p-H3(Ser10) are all highly expressed in HCC827GR cells. Among the three Aurk proteins, the expression of AurkC changes most significantly, which is consistent with the change trend of p-H...

Embodiment 2

[0061] Example 2 Determination of AurkC as the target of kaempferol by Kinase Profiler experiment

[0062] experiment method:

[0063] (1) Add 10 mM kaempferin, 47 kinds of kinases and kinase substrates respectively with Mosquito protein crystallization screening workstation and mix well. After adding 10 mM ATP to each well with an automatic dispenser, incubate at room temperature for 2 hours. (2) After the reaction is finished, filter the reaction solution with a filter membrane, and the rest is a solution containing unconsumed ATP. (3) Use a Biomek instrument to read the value of the remaining ATP. (4) The off-board data was analyzed with IDBS Activity Base software.

[0064] test results:

[0065] target Activity(%) target Activity(%) Abl(h) 79 ICK(h) 96 ALK(h) 90 IGF-1R(h) 114 A-Raf(h) 98 IKKα(h) 97 ATM(h) 99 JAK2(h) 90 ATR / ATRIP(h) 105 JNK2α2(h) 101 Aurora-A(h) 72 Lck(h) 82 Aurora-B(h) 56 LIMK...

Embodiment 3

[0067] Embodiment 3 Kaempferoside can combine with AurkC kinase and inhibit its enzymatic activity

[0068] 1. Through drug binding experiments, it was determined that kaempferrin can bind to AurkC

[0069] experiment method:

[0070] (1) Accurately weigh 0.1 g of CNBr Beads into a cryovial, add 1 mL of Activating Buffer, 800 μL of Coupling Buffer and kaempferol at a final concentration of 10 mM, and invert overnight at 4°C. (2) The next day, take out the kaempferiside-Beads conjugate that was turned overnight at 4°C, add 1mL of Coupling Buffer for centrifugation, add 1mL of Blocking Buffer, and turn over overnight at 4°C. (3) On the third day, take out the kaempferiside-Beads conjugate that was turned overnight at 4°C, add 500 μL 1×PBS to resuspend the kaempferiside-Beads conjugate, and store at 4°C for use. (4) Add the harvested HCC827GR cell protein to the Kaempferoside-Beads conjugate, add 1mL Reaction Buffer 1, and invert overnight at 4°C. (5) On the fourth day, take o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of kaempferiside in the preparation of antitumor drugs. Kaempferoside can specifically bind to AurkC kinase, and inhibit the enzymatic activity of AurkC in a dose-dependent manner, and can significantly inhibit the growth of non-small cell lung cancer cells resistant to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‑TKIs). Growth and proliferation, promoting cell apoptosis, can be used for the treatment of patients with advanced lung cancer, that is, it can overcome the drug resistance of tumor cells to epidermal growth factor receptor-tyrosine kinase inhibitors.

Description

technical field [0001] The invention belongs to the field of pharmacy and relates to the use of kaempferiside in the preparation of antitumor drugs. Background technique [0002] Lung cancer is one of the most important global public health problems. Its morbidity and mortality rank among the forefront of malignant tumors, and the overall prevention and control situation is very severe. [0003] Patients with non-small-cell lung cancer (NSCLC) account for about 85%-90% of the total number of lung cancers. Because the early detection rate of NSCLC in routine chest physical examination (chest radiography or fluoroscopy) is low, and for the vast majority of people in my country, low-dose chest spiral CT that can detect early lung cancer is not used as a routine physical examination item, so there are at least 40% of NSCLC patients are already in the middle and advanced stages when they are first diagnosed, and they have lost valuable opportunities for surgery. The treatment of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7048A61P35/00A61P35/04
CPCA61K31/7048A61P35/00A61P35/04
Inventor 朱峰段秋红王菲张璐汪薇肖娟娟
Owner 朱峰